Meeting
2021 ASCO Annual Meeting
Detection of prognostic cancer-specific circular RNA in plasma.
Authors
Jason Brown
Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Jason Brown , Palak Shah , Josh Vo , Alex Tsodikov , Lena Kleyman , Xuhong Cao , Arul Chinnaiyan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3032)
DOI
10.1200/JCO.2021.39.15_suppl.3032
Abstract #
3032
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
The use of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET in the evaluation of breast cancer heterogeneity.
First Author: Lanell M Peterson
Poster
2012 ASCO Annual Meeting
Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).
First Author: Ines Maria Vaz Duarte Luis
Poster
2024 ASCO Breakthrough
Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.
First Author: Xingliang Tan
Poster
2024 ASCO Annual Meeting
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.
First Author: Jacob Sands